报价延迟最少15分钟:2026/04/25 18:44 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.22 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
2.42/-2.56
|
|
企业价值
103.21M
|
| 资产负债 |
|
每股账面净值
2.87
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
53.74M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD). |
